inflammatory diseases

VYNE Therapeutics Inc (NASDAQ: VYNE) reports Q2 product revenue of $4.0 million compared to $1.5 million in Q2 FY20, driven by the Zilxi product launch in October 2020 and increased demand for Amzeeq.  The gross margin decreased from 85% to 80%. The adjusted EPS loss of $(0.35...

European Medicines Agency (EMA) has established a probable link between heart inflammation and mRNA-based COVID-19 vaccines made by Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA). The EMA said that heart conditions myocarditis and pericarditis must be listed as...

The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD). The approval for the treatment comes as a monotherapy or in combination with immunosuppressive therapy. ...

It seems as if mergers and acquisitions in the healthcare sector has become commonplace, with a lot of biotech companies being main targets. Not a week goes by without multiple discussions about the battle between Valeant Pharmaceuticals (NYSE: VRX) and Allergan(NYSE: AGN). Last week brought...